Chronic Drug-Induced Liver Injury: Updates and Future Challenges
Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing effective treatment. About 20% of patients with DI...
Main Authors: | Qiaoling Wang, Ang Huang, Jia-Bo Wang, Zhengsheng Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.627133/full |
Similar Items
-
Drug-induced liver injury caused by treatment of complications after glucocorticoid therapy for panniculitis: a report of one case
by: CHANG Binxia
Published: (2015-05-01) -
Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study
by: Yang HY, et al.
Published: (2019-03-01) -
Herb-Induced Liver Injury Related to Reynoutria multiflora (Thunb.) Moldenke: Risk Factors, Molecular and Mechanistic Specifics
by: Xing-Ran Zhai, et al.
Published: (2021-09-01) -
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
by: Siyu Fu, et al.
Published: (2020-01-01) -
The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study
by: Zhong-Bin Li, et al.
Published: (2021-08-01)